Exclusivity refers to certain delays and prohibitions on approval of competitor drugs available under the statute that attach upon approval of a drug or of certain supplements.

NKGen Biotech, Inc. declares the commencement of treatment in its initial participant within a Phase 1/2a Study using its own SNK01, aimed for moderate Alzheimer's Disease.

STING agonists are drugs that activate the STING pathway, enhancing immune response against diseases like cancer.

NeuroBo Pharma has filed an Investigational New Drug request with the FDA, seeking approval to commence a Phase 1 trial on compound DA-1726 aimed at combating obesity.

It depends on what type of exclusivity is at issue.

Clover Biopharmaceuticals reports positive initial findings from a phase I trial evaluating SCB-219M, an advanced bispecific Fc-fusion TPO-RA protein developed with CHO cell systems, focusing on safety, efficacy, and pharmacokinetics.

Patents and exclusivity work in a similar fashion but are distinct from one another and governed by different statutes.

PPAR agonists are drugs that activate peroxisome proliferator-activated receptors, aiding in the treatment of metabolic disorders.

While both SPCs and PTEs serve the purpose of extending patent protection for pharmaceutical or plant protection products, there are several key differences to consider.

Innovent and Xuanzhu Initiate Joint Study Exploring Dual Treatment Approach with Sintilimab (PD-1 Blocker) Plus a New ADC Drug for Progressive Solid Cancers in China.

Passive and active drug delivery are two distinct approaches used to improve the targeted delivery of drugs within the body.

Endothelin receptor antagonists (ERAs) are drugs that block endothelin receptors, used to treat conditions like pulmonary arterial hypertension and Raynaud’s phenomenon.